Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 139

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 139
---
 number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. 

We do not intend to pay dividends on our capital stock, so any returns will be limited to the value of our stock. 

We have never declared or paid any cash dividends on our capital stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our capital stock. Any return to stockholders will therefore be limited to any appreciation in the value of their stock. 

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. 

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. These provisions, among other things: 

•establish a classified board of directors so that not all members of our board are elected at one time; 

•permit only the board of directors to establish the number of directors and fill vacancies on the board; 

•provide that directors may only be removed “for cause” and only with the approval of two-thirds of our stockholders; 

•authorize the issuance of “blank check” preferred stock that our board could use to implement a stockholder rights plan (also known as a “poison pill”); 

•eliminate the ability of our stockholders to call special meetings of stockholders; 

•prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; 

•prohibit cumulative voting; 

•authorize our board of directors to amend the bylaws; 

•establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and 

 84

•require a super-majority vote of stockholders to